TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19906348
Drug: Aripiprazole 30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 30 mg/d
Study: 10904025
Drug: Icatibant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant (10 mg IV) coadministered with perindoprilat (1.5 mg IV)
Study: 10904025
Drug: Perindoprilat (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat (1.5 mg IV)
Study: 9519139
Drug: SPF 17
Normalized name: ZINC OXIDE 114 mg in 1 mL TOPICAL CREAM [Pacifica CC broad spectrum SPF 17 LIGHT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPF 17 broad spectrum sunscreen cream
Study: 3030387
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg and over
Study: 31731111
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg by mouth daily for 90 days
Study: 20616365
Drug: Short-range PCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-range PCR (used in combination with TP-PCR)
Study: 15516352
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg/ml in plain solution
Study: 15516352
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg/ml with glucose 50 mg/ml (hyperbaric solution)
Study: 10596996
Drug: Hepcon group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepcon group (360±80 IU/kg of heparin)
Study: 10596996
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (300 IU/kg of heparin)
Study: 2027802
Drug: Subcutaneous long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous long-acting epinephrine (Sus-Phrine), 0.005 ml per kg before albuterol aerosols
Study: 2027802
Drug: Albuterol aerosols
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosols
Study: 7023861
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atropine and terbutaline sulfate (0.005 mg/kg)
Study: 7023861
Drug: Terbutaline sulfate
Normalized name: Terbutaline Sulfate
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline sulfate (0.005 mg/kg)
Study: 30840136
Drug: 90 g
Normalized name: Fora G90 Glucose Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g h-1 glucose-fructose
Study: 30840136
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g h-1 glucose-fructose
Study: 23858719
Drug: Specific immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immune therapy (SIT)
Study: 20017325
Drug: Group psychological
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychological therapy for depression and anxiety during pregnancy (6 sessions, 1.5 hours each)
Study: 20017325
Drug: Group psychological
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychological therapy
Study: 15336297
Drug: Paroxetine (PAR)
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine (PAR) 20 mg
Study: 15279537
Drug: 5-session Preparing
Normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-session Preparing for the Drug Free Years Program (PDFY)
Study: 10601133
Drug: SR49059 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR49059 (300 mg oral dose)
Study: 7582278
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 750 micrograms twice daily
Study: 7582278
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 1000 micrograms twice daily
Study: 1791718
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g, 1 tablet, 4 times a day for 20 days)
Study: 1791718
Drug: Venter (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venter (1 g, 1 tablet, 4 times a day for 20 days)
Study: 6972165
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (220 mg zinc sulfate twice daily for a month)
Study: 25403296
Drug: Noofen (15‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noofen (15‐20 mg/kg, 500‐700 mg per day, perorally in 2‐3 doses)
Study: 25403296
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of multivitamins (Control)
Study: 16194890
Drug: Post-treatment hemoglobin
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment hemoglobin values
Study: 22658127
Drug: Anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 antibody (BMS-936558) at a dose of 0.1 to 10.0 mg/kg every 2 weeks for up to 12 cycles.
Study: 22658127
Drug: Anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 antibody (BMS-936558) at a dose of 0.1 to 10.0 mg/kg every 2 weeks.
Study: 20467629
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg taken four times a day for one week)
Study: 17874878
Drug: Concurrent alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent alcohol and tobacco treatment
Study: 15564947
Drug: Probenecid (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (500 mg)
Study: 15564947
Drug: Quinidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (800 mg)
Study: 7946872
Drug: bupivacaine 100
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 100 mg and morphine 3 mg (group 3)
Study: 7946872
Drug: bupivacaine 100
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 100 mg and morphine 1 mg (group 2)
Study: 7946872
Drug: bupivacaine 100
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 100 mg (group 1)
Study: 31999376
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously once every 6 months for 12 to 36 months
Study: 28182503
Drug: Glucose Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose Nasal Spray (GLUC NAS)
Study: 28182503
Drug: Caffeine Nasal
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine Nasal Spray (CAF NAS)
Study: 28182503
Drug: Placebo Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray
Study: 26142584
Drug: Sildenafil dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil dosage frequency ≤1 weekly
Study: 26142584
Drug: Sildenafil dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil dosage frequency 2-3 weekly
Study: 26142584
Drug: Sildenafil dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil dosage frequency 4-7 weekly
Study: 23033239
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (mean weekly dose of 88,865 IU)
Study: 17525774
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% with hyaluronidase 15 IU/ml
Study: 12660058
Drug: VIT (venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIT (venom immunotherapy)
Study: 8543545
Drug: Three-times-weekly, bilateral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-times-weekly, bilateral, brief pulse ECT
Study: 8543545
Drug: Twice-weekly ECT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly ECT plus one simulated treatment per week
Study: 27185843
Drug: Trabectedin 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.1 mg/m² plus Doxorubicin 60 mg/m²
Study: 27185843
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m²
Study: 24607844
Drug: Exercise Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Therapy (high dose, supervised low-tech trunk exercise)
Study: 9552779
Drug: Incisional morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional morphine (5 mg)
Study: 9552779
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (5 mg)
Study: 9552779
Drug: Overall morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall morphine and acetaminophen consumption
Study: 7925214
Drug: Pancuronium 0.085
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.085 mg kg‐1
Study: 2973531
Drug: Plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived hepatitis B virus vaccine
Study: 2973531
Drug: DNA recombinant
Normalized name: somatropin (recombinant DNA origin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA recombinant hepatitis B virus vaccine
Study: 791318
Drug: Intramuscular metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular metoclopramide before effervescent aspirin
Study: 791318
Drug: Effervescent aspirin
Normalized name: aspirin Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent aspirin alone
Study: 24584055
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral treatment (ICBT) with systematic exposure to IBS symptoms and related situations
Study: 24584055
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral treatment without systematic exposure (ICBT‐WE)
Study: 20178877
Drug: Active acupressure
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active acupressure treatments
Study: 20178877
Drug: Placebo acupressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo acupressure treatments
Study: 19031154
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation of number and length
Study: 16553019
Drug: Tiagabine 2
Normalized name: tiaGABine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 2 mg
Study: 12735531
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy aimed at ADL activities
Study: 1906447
Drug: Psyllium preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium preparation (5 ml, 3 times a day for 6 days)
Study: 6408016
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet (200 kcal) with T3 supplementation (150 micrograms daily)
Study: 23171524
Drug: Patient-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-oriented treatment decision aid (PORTDA-diab) offered immediately before quarterly practice consultation.
Study: 17545705
Drug: Vicriviroc 10
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 10 mg twice a day
Study: 17545705
Drug: Vicriviroc 25
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 25 mg twice a day
Study: 17545705
Drug: Vicriviroc 50
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 50 mg twice a day
Study: 12069671
Drug: Early statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early statin therapy (median, 2.0 days after ACS; n = 3952)
Study: 12069671
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy (n = 8413)
Study: 2883104
Drug: S 3341
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 3341 (1 and 2 mg)
Study: 31977878
Drug: Multicomponent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent treatment program for 12 weeks
Study: 24954843
Drug: Cortisol administration
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administration (20mg intravenously) before retrieval
Study: 24954843
Drug: Cortisol administration
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administration before encoding
Study: 9762492
Drug: Indirect therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect therapy
Study: 18821106
Drug: Usual levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual levels of community‐based speech‐and‐language therapy
Study: 15353155
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) treatment for 1-4 weeks
Study: 3826809
Drug: Oral phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phenytoin capsules (18 mg/kg)
Study: 3826809
Drug: Oral phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phenytoin suspension (18 mg/kg)
Study: 3826809
Drug: Oral phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phenytoin (both forms)
Study: 30730214
Drug: Free-of-charge subdermal
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-of-charge subdermal etonogestrel implant (SEI)
Study: 30730214
Drug: Partially paid
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially paid subdermal etonogestrel implant (SEI)
Study: 30730214
Drug: Free-of-charge and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-of-charge and partially paid subdermal etonogestrel implant (SEI)
Study: 28349730
Drug: CHO (7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (7.5% CHO; 5 mL · kg‐1 per exercise session; n = 6)
Study: 28349730
Drug: PLA (0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA (0% CHO, taste- and volume-matched solution; n = 6)
Study: 26717860
Drug: LCPT (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPT (once daily at 0.17 mg/kg/d)
Study: 26717860
Drug: IR-Tac (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR-Tac (twice daily at 0.1 mg/kg/d)
Study: 20018274
Drug: Beta-blockers (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (Group 2)
Study: 20018274
Drug: Anxiolytics (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytics (Group 3)
Study: 15102874
Drug: 1.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/day FTY720
Study: 15102874
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day FTY720
Study: 12226034
Drug: IV preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV preparation (80 mg in 2 mL vial diluted with 2 mL saline containing preservatives)
Study: 12226034
Drug: Preservative-free preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free preparation (300 mg in 5 mL solution)
Study: 12226034
Drug: IV preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV preparation
Study: 12226034
Drug: Preservative-free preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free preparation
Study: 9839330
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration before hepatic DSA
Study: 8205581
Drug: Rembrandt Lighten
Normalized name: Rembrandt
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rembrandt Lighten Bleaching Gel
Study: 2732125
Drug: Oral rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral rifampicin 900 mg/day plus oral doxycycline 200 mg/day for 45 days (Regimen A)
Study: 2732125
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline 200 mg/day for 45 days plus im streptomycin 1 g/day for 21 days (Regimen B)
Study: 2732125
Drug: WHO regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO regimen combining oral tetracycline 2 g/day for 21 days plus im streptomycin 1 g/day for 14 days (Regimen C)
Study: 26159140
Drug: Silver-Care-Robot Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver-Care-Robot Program (conducted twice a week for 5 weeks)
Study: 21600084
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of compound azintamid (2 tablets 3 times a day) and domperidone (10 mg 3 times a day) for 4 weeks
Study: 21600084
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of compound azintamid and domperidone
Study: 21600084
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg 3 times a day) for 4 weeks
Study: 10326889
Drug: LNG-containing oral
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-containing oral contraceptive minipills (30 mirog)
Study: 1778327
Drug: JNIH-7 (mono-component
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNIH-7 (mono-component vaccine)
Study: 1778327
Drug: JNIH-6 (two-component
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNIH-6 (two-component vaccine)
Study: 7095559
Drug: prednisolone/azathioprine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone/azathioprine therapy
Study: 31914940
Drug: Rifampin, 600
Normalized name: Rifampin, 600 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin, 600 mg daily for 6 weeks
Study: 30935657
Drug: Ocriplasmin (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin (0.125 mg intravitreal injection)
Study: 28881220
Drug: Daily life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily life EF behavior
Study: 17321928
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg/kg IV
Study: 15138439
Drug: Methamphetamine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (0.15 mg/kg)
Study: 2438923
Drug: Pirmenol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol hydrochloride (200 to 400 mg daily)
Study: 28539539
Drug: Bococizumab 50
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 50 mg
Study: 28539539
Drug: Bococizumab 100
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 100 mg
Study: 28539539
Drug: Bococizumab 150
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 150 mg
Study: 23438223
Drug: Taste-matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taste-matched placebo (PLB) solution
Study: 19188925
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin (5 pmol kg(‐1) min(‐1))
Study: 16507585
Drug: Fontolizumab 4
Normalized name: Fontolizumab
DrugBank: Fontolizumab (DB05111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fontolizumab 4 mg/kg
Study: 16507585
Drug: Fontolizumab 10
Normalized name: Fontolizumab
DrugBank: Fontolizumab (DB05111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fontolizumab 10 mg/kg
Study: 15640628
Drug: Afelimomab 1
Normalized name: afelimomab
DrugBank: Afelimomab (DB04956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afelimomab 1 mg/kg for 3 days
Study: 8298071
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride (12 mg dose) administered after a standardized meal
Study: 8298071
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride (12 mg dose) administered after fasting for 12 hours
Study: 3106096
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg for 5 days
Study: 3106096
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg intravenous bolus followed by 1.6 mg/hour for 9 hours)
Study: 2661789
Drug: MBDL regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBDL regimen (metoclopramide 8 mg/kg, benztropine 0.04 mg/kg, dexamethasone 0.7 mg/kg, lorazepam 0.1 mg/kg)
Study: 2661789
Drug: Chlorpromazine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (3.3 mg/kg in four doses over 24 hours)
Study: 31292845
Drug: Tongxiening Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxiening Granules (TXNG) 5 g per time combined with pinaverium bromide Tablet simulator (50 mg per time), 3 times per day for 6 weeks
Study: 31292845
Drug: TXNG simulator
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXNG simulator (5 g per time) combined with pinaverium bromide Tablets (50 mg per time), 3 times per day for 6 weeks
Study: 25070686
Drug: (177)Lu-EDTMP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: (177)Lu-EDTMP at a dose of 1,295 MBq (group A)
Study: 25070686
Drug: (177)Lu-EDTMP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: (177)Lu-EDTMP at a dose of 2,590 MBq (group B)
Study: 7984592
Drug: Detoxication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detoxication therapy at the start of combined treatment
Study: 7984592
Drug: Detoxication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detoxication therapy